Literature DB >> 17983622

Cystatin C is associated with an increased coronary atherosclerotic burden and a stable plaque phenotype in patients with ischemic heart disease and normal glomerular filtration rate.

Giampaolo Niccoli1, Micaela Conte, Roberta Della Bona, Luca Altamura, Massimo Siviglia, Ilaria Dato, Giuseppe Ferrante, Antonio M Leone, Italo Porto, Francesco Burzotta, Salvatore Brugaletta, Luigi M Biasucci, Filippo Crea.   

Abstract

OBJECTIVE: Cystatin C (Cys-C) is an accurate marker of renal function. Recent studies have shown that serum Cys-C levels predict the risk of cardiovascular events. The causes of this association, however, are largely unknown. METHODS AND
RESULTS: Seventy consecutive patients (age 62+/-12, male sex 87%) undergoing coronary angiography because of typical chest pain and found to have coronary artery disease were included in the present study. Patients with abnormal creatinine-derived glomerular filtration rate (<90ml/min/1.73m(2)) were excluded in order to avoid the well-known effect of overt renal insufficiency on coronary atherosclerosis. Coronary angiography was evaluated by two expert angiographers who assessed disease severity and extent according to the Sullivan's score and lesion morphology. In all patients, Cys-C and C-Reactive Protein (CRP) serum levels were measured on admission. Multivariable analysis was performed to assess independent predictors of angiographic measures. Diabetes was the only predictor of disease severity (p=0.005), while male sex (p=0.03), hypercholesterolemia (p=0.04), diabetes (p<0.0001) and Cys-C (p<0.0001) were independent predictors of disease extent. Independent predictors of smooth lesions were diabetes (p<0.001) and Cys-C (p=0.005). No correlation was found between Cys-C and CRP serum levels (p=0.6).
CONCLUSION: Cys-C is associated with coronary atherosclerosis extent and a smooth lesion morphology. The long-term prognostic role of Cys-C might be accounted for by a greater atherosclerotic burden, a necessary substrate for plaque destabilization.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17983622     DOI: 10.1016/j.atherosclerosis.2007.09.022

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  16 in total

1.  The role of cystatin C in vascular remodeling of balloon-injured abdominal aorta of rabbits.

Authors:  Xiang-Jun Wu; Zhao-Qiang Dong; Qing-Hua Lu
Journal:  Mol Biol Rep       Date:  2014-07-01       Impact factor: 2.316

2.  The potential of Cystatin C and small dense LDL as biomarkers of coronary artery disease risk in a young Indian population.

Authors:  Anjali Manocha; Flora Gupta; Rajneesh Jain; Seema Bhargava; Mamta Kankra; Sabari Das; L M Srivastava
Journal:  Mol Cell Biochem       Date:  2013-12-20       Impact factor: 3.396

3.  Impact of N-acetylcysteine on contrast-induced nephropathy defined by cystatin C in patients with ST-elevation myocardial infarction undergoing primary angioplasty.

Authors:  Michal Droppa; Steffen Desch; Patrick Blase; Ingo Eitel; Georg Fuernau; Gerhard Schuler; Volker Adams; Holger Thiele
Journal:  Clin Res Cardiol       Date:  2011-06-28       Impact factor: 5.460

4.  Serum cystatin C and the incidence of hypertension in type 1 diabetes mellitus.

Authors:  Karine Sahakyan; Barbara E K Klein; Kristine E Lee; Michael Y Tsai; Ronald Klein
Journal:  Am J Hypertens       Date:  2010-09-30       Impact factor: 2.689

5.  Mild renal dysfunction and metabolites tied to low HDL cholesterol are associated with monocytosis and atherosclerosis.

Authors:  Anjali Ganda; Martin Magnusson; Laurent Yvan-Charvet; Bo Hedblad; Gunnar Engström; Ding Ai; Thomas J Wang; Robert E Gerszten; Olle Melander; Alan R Tall
Journal:  Circulation       Date:  2013-02-01       Impact factor: 29.690

6.  Cystatin C, other markers of kidney disease, and incidence of age-related cataract.

Authors:  Barbara E K Klein; Michael D Knudtson; Peter Brazy; Kristine E Lee; Ronald Klein
Journal:  Arch Ophthalmol       Date:  2008-12

7.  Cystatin C and asymptomatic coronary artery disease in patients with metabolic syndrome and normal glomerular filtration rate.

Authors:  Xie Qing; Wang Furong; Liu Yunxia; Zhang Jian; Wang Xuping; Gao Ling
Journal:  Cardiovasc Diabetol       Date:  2012-09-14       Impact factor: 9.951

8.  The ethnicity-specific association of biomarkers with the angiographic severity of coronary artery disease.

Authors:  C M Gijsberts; A Seneviratna; I E M Bank; H M den Ruijter; F W Asselbergs; P Agostoni; J A Remijn; G Pasterkamp; H C Kiat; M Roest; A M Richards; M Y Chan; D P V de Kleijn; I E Hoefer
Journal:  Neth Heart J       Date:  2016-03       Impact factor: 2.380

9.  Cystatin C: A prognostic marker after myocardial infarction in patients without chronic kidney disease.

Authors:  Leila Abid; Salma Charfeddine; Samir Kammoun; Mouna Turki; Fatma Ayedi
Journal:  J Saudi Heart Assoc       Date:  2015-10-09

10.  Association of epicardial adipose tissue with serum level of cystatin C in type 2 diabetes.

Authors:  Tomomi Murai; Noriko Takebe; Kan Nagasawa; Yusuke Todate; Riyuki Nakagawa; Rieko Nakano; Mari Hangai; Yutaka Hasegawa; Yoshihiko Takahashi; Kunihiro Yoshioka; Yasushi Ishigaki
Journal:  PLoS One       Date:  2017-09-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.